Michmerhuizen, A. R., Chandler, B., Olsen, E., Wilder-Romans, K., Moubadder, L., Liu, M., . . . Speers, C. (2020). Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Front Endocrinol (Lausanne).
Style de citation ChicagoMichmerhuizen, Anna R., et al. "Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells." Front Endocrinol (Lausanne) 2020.
Style de citation MLAMichmerhuizen, Anna R., et al. "Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells." Front Endocrinol (Lausanne) 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.